Izindaba

I-Delhi entsha, ngoJuni 22 (XINHUA) - Umenzi wokugomela i-India uMakech u-Covaxin ukhombise ukusebenza ngamaphesenti angama-77,8 ezigabeni zesigaba III, kusho abezindaba zendawo eziningi ngoLwesibili.

"I-Covaxin ye-Bharat Biotech ngamaphesenti angama-77,8 isebenza ngokuvikela nge-Covid-19, ngokwemininingwane evela ezivivinyweni zesigaba III ezenziwe kubahlanganyeli abangama-25,800 e-India," kusho umbiko.

Izinga lokusebenza kahle liphume ngoLwesibili ngemuva kokulawulwa kwezidakamizwa General Committee of India (i-DCGI) iKomidi Lesihloko (sec) sahlangana futhi saxoxa ngemiphumela.

Inkampani yezemithi ibithunyelwe idatha yesigaba sesigaba III somuthi wokugomela ku-DCGI ngempelasonto.

Imibiko ithe inkampani kulindeleke ukuthi ibambe umhlangano "wokuhanjiswa kwangaphambili" nabaphathi be-World Health Organisation ngoLwesithathu, ukuxoxa ngemikhombandlela yokulethwa kokugcina kwemininingwane nemibhalo edingekayo.

I-India yaqala ukugonywa ngobuningi nge-Covid-19 ngoJan 16 ngokuphatha imigomo emibili eyenziwe e-India, okuyi-Covialield ne-Covaxin.

I-Serum Institute of India (i-SII) ikhiqiza i-AstraZeneca-Oxford University

Umuthi wokugomela iSputnik v weSputkhok v waqalwa nakuleli lizwe. Enditem